Document Type

Article

Publication Date

1-1-2024

Abstract

Introduction

This study aimed to determine whether encephalopathy is associated with such COVID-19 outcomes as disease severity, mortality, respiratory failure, intensive care unit (ICU) admission, duration of ventilator dependence, and length of ICU and hospital stay.

Methods

We performed a subgroup analysis comparing outcomes in patients with and without encephalopathy, based on data from a nationwide retrospective cohort study among adult patients hospitalized with COVID-19 at 37 hospital sites in the Philippines. The patient outcomes included for analysis were disease severity, mortality, respiratory failure, ICU admission, duration of ventilator dependence, and length of ICU and hospital stay.

Results

Of a total of 10 881 COVID-19 admissions, 622 patients had encephalopathy. The adjusted hazard ratios (aHR) for mortality among mild and severe cases were 9.26 and 1.63 times greater (P < .001), respectively, in the encephalopathy group compared to the no-encephalopathy group. Encephalopathy was associated with increased risk of severe COVID-19 (adjusted odds ratio [aOR]: 7.95; P < .001), respiratory failure (aHR: 5.40; P < .001), longer hospital stays (aOR: 1.36; P < .001), and admission to the ICU (aOR: 4.26; P < .001). We found no sufficient evidence that encephalopathy was associated with length of ICU stay (aOR: 1.11; P = .522) or duration of ventilator dependence (aOR: 0.88; P = .428).

Conclusions

Encephalopathy was associated with COVID-19 severity, mortality, respiratory failure, ICU admission, and longer hospital stays.

Included in

Neurology Commons

Share

COinS